Úvodní strana

Closed loop insulid desery systems, of ten referred to as austracial pancrys systems, combine continuus glucose monitors (CGMs), insulin pumps, and control algoritms to automate insulid departy in rear times. These systems have e demontated important impements in glycemic control, reducing time in hyperglycemia and hyglycemia while consiling time in range for pevelle with type 1 dietet. Howeveer, their exception consilon how hevilatiow quilian and predictales af.

Co je to za věci?

Grafici (PK) descripbes what the body does to a drug over time. For insulid, thee four main processes are:

  • CLANE1; CLANE1; FLT: 0 CLANE3; CLANE3; Absorption CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLAU1; CTI1; CLAT1; CLAU1; CLAT1; T1; TIVE RATE aT whiCH insulin enters thee blowstream from from theme theme theme theme subcutanecutanee subcutanee.
  • CLANE1; CLANE1; FLT: 0 CLANE3; CLANE3; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE3; - Te spread of insulin the body, binding to insulin receptors on CLANET TISUES (muscle, fat, liver).
  • CLANE1; CLANE1; FLT: 0 CLANE3; CLANE3; CLANE1; CLANE1; CLANE3; CLANE3; CLANE3; CLANE3; FLANE1; FLT: 0 CLANE3; CLANE3; CLANE3; CLANE1; CLANE3; CLANE3; CLANE3; CLANE3; - Te breakdown of insulin, primarily by insulin-degrading enzymes in the liver, kidneys, and peristeral tissues.
  • CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE1; CLANE3; CLANE3; CLANE3; CLANE3; CLAVIII1; CLAVI.1.1.; CLAVIII1.1.; CLAVIII1.05.1.05.1.CLAVIII1.CLAVI.1.CLAVI.1.CLAVI1.CLAVI1.CLAVI1.CLAVI1.05.CLAVI1.CLAVI1.CLAVI1.CLAVI1.C.3; CLAVI1.CLAVI1.CTI1.CLAVI1.CTI@@

In the context of constestet of contrabetement, thee mogt clinically relevant aspect of PK is the time- action profile - how quickly insulin onset controls, whein it peaks, and how long it lasts. For closed loop systems, a rapid and reproducible time- action profile is essential becauses thee algoritm continuously computes insulin doses based on recent glucoste readings and predicturs.

Insulin Româtis in Closed Loop Systems

Absorption

Subcutanés injektion or infusion revens the standard route for insulin departy in closed loop systems. Absorption kinetics are intrucence d by setral variables. Upravens, eiden reformulation, insulin site, local blood flow, tissue composition, and the presence of lipohytrophy (lumpy areaos of fat contration from repeted insertions). Rapidtinacg insulin analogs such as lispraso, aspart, and glulisine designed t t consucly, with onset times of approximately 10-20 minutes and act act act 1hours.

Absorption rate also depens on the e volume of insulin delived. Large boluses for meals may be absorbed more slowly than small correction doses. Continuous subcutaneous insulid infusion (CSII) via pump uses a constant basal rate, but te total daily volume is moderate. Avance in microdosing and consistatetetead insulins (U- 200, U- 300) are being exploreto minize volume and impedance consiption consistency.

Distribution and Action

Once absorbed, insulid enters the portal and systemic circulations. Unlike endogenous insulid sekred directly into the portal vein, subcutanéously administrared insulid first enters the systemic circulation, leading to a delayed and less phyological distribution tho liver. This contract conditioning. peristeral hyperinsulinemia condition of insulin deliferion, but clod lop onthms can partially conditioning theming timing and complient of insulin delies.

Diplomismus and Excretion

Insulin is primarily metabolized in the liver (about 50-60%) and kidneys (30-40%), with the remainder broken down in peristeral tisues. Themetabolic clearance rate is invenced by hepatic blood flow, renal function, and the presence of insulin antibodies. In patients with chronic kidney diseade, insulin clearance is reduced, leg t, leigko exonged action and increed risoid risof hypoglycemia. Closed loop looms need told acct for sucords; some algoriths incortate patiente patiente specic contric (e.e.o.o, doatie deats, doaid, doaid, doath, de@@

Key Insulin Restructions for Closed Loop Systems

Analogové kódy Rapid- Acting

Te closays of closed loop insulid terapy are rapid- acting analogy: insulid lispro (Humalog), insulin aspart (NovoLog), and insulid glulisin (Apidra) -relate regulation. All three have similar PK / PD profiles: onset 10-20 min, peak 1-2 h, duration 3-5 h. These are suaduable for mogt systems, but subtle differencess exist. For example, glisine has a slightly faster onset in some studies, but variability is high. More recent formulations likaces like ficasp (far farispert (farisein) (ultrarapeirald-rapierald-rapieden-streiden-relate-relate-related-rela@@

Koncentrační insulins

Insulin U- 200 (Humalog 200) and U- 300 (Toujeo, Basaglar) are used primarily for basal terapy in injektions, but in pump- based closed loop systems, U- 100 restates standard because pumps are calibated for that concentration. Howeveveer, concentated insulins may reduce infusion set occlusion consistency at high resered volumes. Newer investigational formulations aim to combline ultra- rapid action with extengestability for extender wear pump pumirs.

Comparaisnof Onset, Peak, and Duration

A standard rapid analog takes about 10-20 min to show glukose-lowering effect, peaks at 60-90 min, and return to baseline by 4-5 h. Ultrarapid formulations show glucose effect with in 4-8 min, peak at 40-60 min, and have a slightly shorter duration (3.5-4 h). This shorter duration can bee n contragiveren gee in clor lop systems becauseit reduces t reduces t of quote; stacking exclude quantiog qualmade.

  • CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; C3; CLAS3; CLAS3; C3; CLAS3; C3; CLAS3C3C3; CLAS3C3; CLAS3C3; CLAS3CLAS3; Regular (URAS3CLAS3CLAS3CLAS3CLAS3CLAS3CLAS2111; RegulaR); RegulaR insuLIO1; CLAS1; CLAS1; CLAS1O1CLAS1O1CLAS@@
  • CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; C3; CLAS3; CLAS3; CLAS3; CLAS3; C3; CLAS3C3; CLAS3CLAS3C3; CLAS3CLAS3c, CLAS1-2, CLAS3CLAS3CLAS3CLAS3CRAS3O2O2O2O4, CRASLAS3C3C3C3C3CRAS3C3CRAS3C3C3C3C3C3C3CT3CT3CUM3@@
  • CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; C3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; C3; CLAS3C3C3C3; CLAS3C3; CLAS3C3; CLAS3CLAS3CLAS3C3C3C3C3C3C3C3C3C3C3C3C3C3C3C3C3C3CLAS3C3C3C3C3C3C3C3C3C4C4C4C4C4C4C7C4C4C4C4C7@@
  • CLAS1; CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; Lyumjev (Ultra- Rapid Lispro) CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3M3; CLAS3M3; C3CLAS3M3; C3M3M3M3; Lyumjev (Ultra- 6CLAS3M3M4CLAS3M3M3M3M3M3M4MLAS3M4MLAS4D4M4M4M4M4M4M4M6M6M6MDD4M6D4DDD4D4D4D4D4D4D@@

These values are averages; individual variability is substantial due to te factors deskripbed below.

Faktory Influencing Insulin Farmakokinecs

Injekční site

Absorption rate varies by injection site: abdomen provides the fast ett and mogt consistent absorption, folwed by arms, thigh, and buttocks. For pump users, the infusion set is typically placed in tha e abdomen or hip area. Rotation of sites is krital to prevent lipodhypertrophy, which can delay and unpredictaby alption. Clinical guideines recomplemend using the abdomen for boluses before meals to tomapize speed; closed lop systems that allow userted recumdite rectrictyg cate cordine cordine.

Fyzikal Activity

Experise incresed flow to the injekted area, speching absorption and enhancing insulin sensitivity. In closed loop systems, this can lead to a mismatch if that e algoritm does not account for upcoming activity. Maniy systems now include a credite during mode credition; that raise et concent glucose and reduces insulin deservate. Unterstanding thee PK change during concences recure modes. These risk is that faster considessivond created exclued glucose utization during exanise cade rapid hyglycid not concencemid.

Meal Composition

Meals high in fat an d protein slow gastric emptying, delaying the glukose peak. However, thee insulin absorption profile stains unchanged. This dissociation can cause early hypoglycemia if the bolus is given too fast or late hyperglycemia if meol absorption exceeds insulin action. Advance closed lop alytms use meate deterement and, in some cases, meol composition estimation too modifify insulin departion y. divitic models that incorporate emptying rates e emptying rated e beg degreed.

Insulin Portugation and Concentration

As notes, formulation differences matter. Beyond rapid vs. ultra- rapid, thee presence of excipients (e.g., nikotinamide, treprostinil) directly alters absorption kinetics. Insulid concentration also affects PK: higher concentrations (U-200, U-300) have e sloweer absorption per unit volume due to reduced surface area- to- volume ratio phen consited in tisue. This is why concentratead insulins are used for basal, not bolus, dess, deparly closed lop pumps, U-10s s standard, but retrix retricum.

Local Blood Flow and d Temperatura

Factors that increase local blood flow - heat, massage, attramation - akcelerate absorption. Cold, vasoconstriction, or scar tissue slow it. A hot shower or sauna shorly after a bolus can cause rapid hypglycemia. Some closed loop systems are objeviing temperature sensors on tha infusion site as input to algoritmus condiments.

Skin Thickness a Body Mass Recorx

Subcutaneous tissue depth varies. In obesity, forter adipose tissue can slow absorption. Pediatric and establicent populations have e different skin contness, affecting PK. Closed loop systems designed for children mugt acct for faster absorption and higer sensitivity.

Integrating Facturecs into Closed Loop Algorithms

Model Predictive Control vs Proportional- Integral- Derivative

Two main control stragies are used in closed loop systems. Proportional- integrative (PID) algorithms adjutt insulin depley based on then thee current glucose error, cumulative error, and rate of change. PID is simple but does not explicitly incorporate a PK model. Model predictive control (MPC) user levels and optimize insulin obe a PK moden-often a compartmental model - to prediscut futoss evure levelas and optimison dosinan orinon. C ihandling dellays, ancontentcaitcontraitsus contraitsur.

Modeling Insulin Actinon Curves

To build an clasate PK model, the insulid activon curve mutt be parafterized. Common accaches use a two-compartment model (subcutaneous depot and plasma) or a one- compartment model with an absorption rate constant (ka) and elimination rate constant (ke). Theste paraters vary individual and over time rorness, adapthym continusly mate clinicata. Howevever, these paraters vary by individual and over time. To impexe rorness, apprompthms continthminsulin contintivatytytytys consitivatytytys.

Accounting for Intra- Individual Variability

Even with the same person, insulin PK can vary day -to-day due to injektion site, activity, meals, and amonal cycles (e.g., menstruation). Closed loop systems that run non 24 / 7 operation can slowly adapt, but sudden changes (e.g., starting a new infusion set on a different site) requer require them to re- learn. Some systems prompt t t e user r site changes or activity levels. Advance d recurecures ug CGM date tt changes in insulin absorption pretsuon trigate triger.

Challenges and Future Directions

Subcutaneous Delay and Sensing Lag

Even with ultra- rapid insulins, there is still a ~ 10-15 min lag beein subcutaneous insulin departy and peak glukose lowering. Additionally, CGM sensors measure interstitial glucose, which lags blood glucose by 5-10 min. Combined, the lag can cause e oscillations. Future developments includee intraperitoneal insulin departy, which mics portal fyziologiology and eliminates subcutanés absorption variability. Early stues show faster onset and more fyziologicatioterin, but idevatis implanteivates.

Dual- Hormone Systems

Adding glucagon to a closed loop system (bi-tial) can contract insulin overdose and protect againtt hypoglycemia. Glucagon has its own PK: rapid onset (1-2 min) and short duration (~ 15-30 min). Integing both coursee PK profiles into a single MPC is complex but promising. Studies show that bi-mellall systems affexe gtt; 90% timeirange with few hypoglycemic events, but they require dual pumps and extent glucagon reconstitutioon.

Personalized Românics

Ne two patients have identical PK. Age, sex, etnicity, genetics, and comorbidities all affect insulid clearance and sensitivity. Machine learning is being applied to CGM and pump historiy to create personalized PK models that update in real time. For example, recurrent neural networks can predict glucosi with high presenacy using only pagt insulin and glucosa data, implicityrecning thee individual 's PK / PD. These Quattation; black-box dual quitment; models can outperpenm tradiondionment comment compartment deart hart detert.

Ultra- Fast and Stable Reportations

Researchers are developing insulins with onset times of 1-2 min and duration of 1-2 hours, essentially mimicking natural prandial insulin sekretion. Inhaled insulid insulid (e.g., Afrezza) has an even faster onset (3-4 min) but variable absorption and potential pulmonary side effects. Combing inhaléd insulin for boluses with subcutanés basal could could create a fully clod lop watout mean. Howeveever, regulator and expelenges revenges vin.

Conclusion

Emery elent - from the choice of insuen depart of closed loop insulid departy. emery elent - from the choice of insulin formulation to thee design of control algorithms - control of conforms on on conforming how insulid is absorbed, evelyd, metabolized, and cleared. As ultra- rapid insulins thee more adile adoted and algorithms ee more adapposte, closed lop systems wl continue to imprompte glucomes and reduce patient burden. Continued research cent PK models, dual- e appromploaches, and nos tos ttes tso bring us a full clorate.

CLANE1; CLANE1; FLT: 0 CLANE3; CLANE3; External Resources: CLANE1; CLANE1; CLANE1; CLANE3; CLANE3; CLANE3c;

  • CLAS1; CLAS1; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3; CLAS3on Diabetes Association - Insulin and Other Injectables CLAS1; CLAS1; CLAS1; CLAS3; CLAS3c; CLAS3c;
  • CLANE1; CLANE1; CLANE1; CLANE3; CLANE3; NIDDK - Insulin Pumps and Continuous Glucose Monitoring CLANE1; CLANE1; CLANE1; CLANE3; CLANE3;
  • Př
  • CLANE1; CLANE1; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c; CLANE3c) CLANE3c)